Sanofi: presents new data for MS drug

(CercleFinance.com) - Sanofi presents new long-term data supporting the safety and efficacy profile of brain-penetrating tolebrutinib.


This data is being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

One-year results from the Phase IIb extension study of brain-penetrating tolebrutinib show strong adherence - 98% of patients continued treatment.

After 48 weeks, mean MRI lesion activity remained low in patients who started or were switched to tolebrutinib 60 mg, it said.

Data from in vitro studies of human microglia support previous observations that tolebrutinib can modulate BTK-dependent inflammatory signalling, Sanofi added.


Copyright (c) 2021 CercleFinance.com. All rights reserved.